drugset / Trial / NCT00314145

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

NCT00314145

Phase 3 Completed 820 enrolled Sanofi
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVaxTM-JE and JE-VAX to the respective homologous virus strain after completion of vaccination course.

Timeline

Start
2005-11
Primary completion
2006-06
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ChimeriVax™-JE Vaccine 0.5 ml Subcutaneous
Comparator JE-VAX® Vaccine 0.5 ml Subcutaneous

Indications